Ultrasmall Biocompatible Bi2Se3 Nanodots for Multimodal Imaging-Guided Synergistic Radiophotothermal Therapy against Cancer

ACS Nano. 2016 Dec 27;10(12):11145-11155. doi: 10.1021/acsnano.6b06067. Epub 2016 Dec 6.

Abstract

Sub-3 nm ultrasmall Bi2Se3 nanodots stabilized with bovine serum albumin were successfully synthesized through a reaction of hydroxyethylthioselenide with bismuth chloride in aqueous solution under ambient conditions. These nanodots exhibit a high photothermal conversion efficiency (η = 50.7%) due to their strong broad absorbance in the near-infrared (NIR) window and serve as a nanotheranostic agent for photoacoustic imaging and photothermal cancer therapy. In addition, they also display radioenhancement with a ratio of 6% due to their sensitivity to X-rays, which makes them a potential sensitizer for radiotherapy. These nanodots were also labled with radioactive 99mTc for quantification of their biodistribution by single-photon-emission computed tomography (SPECT)/computed tomography (CT) imaging. Our work demonstrates the potential of ultrasmall Bi2Se3 nanodots in multimodal imaging-guided synergetic radiophotothermal therapy of cancer.

Keywords: bismuth selenide nanodots; bovine serum albumin; multimodal imaging; radiophotothermal therapy; ultrasmall.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bismuth
  • Multimodal Imaging
  • Neoplasms / therapy
  • Organoselenium Compounds / pharmacokinetics*
  • Phototherapy
  • Selenium Compounds
  • Serum Albumin, Bovine
  • Theranostic Nanomedicine*
  • Tissue Distribution

Substances

  • Organoselenium Compounds
  • Selenium Compounds
  • Serum Albumin, Bovine
  • bismuth selenide
  • Bismuth